Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral ...

During the penetration process of hypersonic glide vehicles (HGV), the maneuvering forms are varied, which brings some challenges for tracking them, such as difficulty in the stable matching of single ...

Creating a highly accurate geological model at a large scale presents a considerable challenge, primarily due to constraints imposed by sparse data availability. A promising strategy to mitigate these ...

Forbes contributors publish independent expert analyses and insights. Gary Drenik is a writer covering AI, analytics and innovation. This voice experience is generated by AI. Learn more. This voice ...

Abstract: When aero-engine inter-shaft bearing operate under extreme conditions, the detection of their faults is crucial for system reliability. However, due to the weak fault signals and strong ...

iRobot transferred all of its equity to Shenzhen Picea Robotics and said it will launch a U.S. subsidiary to protect U.S. consumer data as it emerges from the chapter 11 bankruptcy process The maker ...

Elon Musk's social network X (formerly known as Twitter) last night released some of the code and architecture of its overhauled social recommendation algorithm under a permissive, enterprise-friendly ...

These notes can be used to find top patterns for each category. Note that reading these notes can be much faster than watching videos. Moreover, it can take only take an evening to refresh your ...

In a strategic move that could protect its obesity pipeline from future patent litigation, Roche is paying $100 million to secure a license from Structure Therapeutics. The agreement grants Roche and ...

Google launched four official and confirmed algorithmic updates in 2025, three core updates and one spam update. This is in comparison to last year, in 2024, where we had seven confirmed updates, then ...

Structure Therapeutics’ stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly’s ...